[HTML][HTML] Eye, hepatobiliary, and renal disorders of erlotinib in patients with non-small-cell lung cancer: A meta-analysis
HD Choi, MJ Chang - PloS one, 2020 - journals.plos.org
Background Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors used to treat EGFR mutation positive non-small-cell lung cancer (NSCLC). Skin …
inhibitors used to treat EGFR mutation positive non-small-cell lung cancer (NSCLC). Skin …
Eye, hepatobiliary, and renal disorders of erlotinib in patients with non-small-cell lung cancer: A meta-analysis
HD Choi, MJ Chang - 2020 - ir.ymlib.yonsei.ac.kr
Background Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors used to treat EGFR mutation positive non-small-cell lung cancer (NSCLC). Skin …
inhibitors used to treat EGFR mutation positive non-small-cell lung cancer (NSCLC). Skin …
[引用][C] Eye, hepatobiliary, and renal disorders of erlotinib in patients with non-small-cell lung cancer: A meta-analysis
HD Choi, MJ Chang - PLoS ONE, 2020 - ui.adsabs.harvard.edu
Eye, hepatobiliary, and renal disorders of erlotinib in patients with non-small-cell lung cancer:
A meta-analysis - NASA/ADS Now on home page ads icon ads Enable full ADS view …
A meta-analysis - NASA/ADS Now on home page ads icon ads Enable full ADS view …
Eye, hepatobiliary, and renal disorders of erlotinib in patients with non-small-cell lung cancer: A meta-analysis.
HD Choi, MJ Chang - PLoS ONE, 2020 - search.ebscohost.com
Background: Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors used to treat EGFR mutation positive non-small-cell lung cancer (NSCLC). Skin …
inhibitors used to treat EGFR mutation positive non-small-cell lung cancer (NSCLC). Skin …
Eye, hepatobiliary, and renal disorders of erlotinib in patients with non-small-cell lung cancer: A meta-analysis
HD Choi, MJ Chang - PLOS ONE, 2020 - ideas.repec.org
Background: Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors used to treat EGFR mutation positive non-small-cell lung cancer (NSCLC). Skin …
inhibitors used to treat EGFR mutation positive non-small-cell lung cancer (NSCLC). Skin …
Eye, hepatobiliary, and renal disorders of erlotinib in patients with non-small-cell lung cancer: A meta-analysis
HD Choi, MJ Chang - PloS one, 2020 - pubmed.ncbi.nlm.nih.gov
Background Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors used to treat EGFR mutation positive non-small-cell lung cancer (NSCLC). Skin …
inhibitors used to treat EGFR mutation positive non-small-cell lung cancer (NSCLC). Skin …
Eye, hepatobiliary, and renal disorders of erlotinib in patients with non-small-cell lung cancer: A meta-analysis
HD Choi, MJ Chang - PLoS ONE, 2020 - go.gale.com
Background Many molecular genetic alterations are involved in the pathogenesis and
progression of lung cancer. The epidermal growth factor receptor (EGFR) mutation is a …
progression of lung cancer. The epidermal growth factor receptor (EGFR) mutation is a …
Eye, hepatobiliary, and renal disorders of erlotinib in patients with non-small-cell lung cancer: A meta-analysis
HD Choi, MJ Chang - PloS one, 2020 - yonsei.elsevierpure.com
Background Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors used to treat EGFR mutation positive non-small-cell lung cancer (NSCLC). Skin …
inhibitors used to treat EGFR mutation positive non-small-cell lung cancer (NSCLC). Skin …
Eye, hepatobiliary, and renal disorders of erlotinib in patients with non-small-cell lung cancer: A meta-analysis
HD Choi, MJ Chang - PLOS ONE, 2020 - econpapers.repec.org
Background: Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors used to treat EGFR mutation positive non-small-cell lung cancer (NSCLC). Skin …
inhibitors used to treat EGFR mutation positive non-small-cell lung cancer (NSCLC). Skin …
Eye, hepatobiliary, and renal disorders of erlotinib in patients with non-small-cell lung cancer: A meta-analysis.
HD Choi, MJ Chang - Plos one, 2020 - europepmc.org
Background Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors used to treat EGFR mutation positive non-small-cell lung cancer (NSCLC). Skin …
inhibitors used to treat EGFR mutation positive non-small-cell lung cancer (NSCLC). Skin …